Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

HONG KONG SAR - Media OutReach Newswire - 22 April 2025 - CK Life Sciences Int'l., (Holdings) Inc. ("the Company") announced that the Company will be presenting new data from its cancer vaccine ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in ...

Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...

The study enrolled patients with a PD-L1 combined positive score (CPS) of 10 or more, matching Keytruda's label in first-line ...

HONG KONG SAR – Media OutReach Newswire – 22 April 2025 – CK Life Sciences Int’l., (Holdings) Inc. (“the Company”) announced ...

The following is a summary of “FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 ...

Patients who discontinued cancer immunotherapy because of immune-related adverse events (irAEs) often had durable benefits ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...